EGRIFTA (tesamorelin acetate) · THERATECHNOLOGIES
EGRIFTA is FDA-approved to treat 1 condition.
Details
- Status
- Prescription
- First Approved
- 2010-11-10
- Routes
- SUBCUTANEOUS
- Dosage Forms
- POWDER
EGRIFTA Approval History
What EGRIFTA Treats
1 indicationsEGRIFTA is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Lipodystrophy
THERATECHNOLOGIES's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EGRIFTA FDA Label Details
Indications & Usage
FDA Label (PDF)EGRIFTA is FDA-approved to treat 1 condition.
Track EGRIFTA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.